Publication details

Examining Endothelial Dysfunction and The Effect of Topical Treatment with Prostaglandin E1 In Diabetics Suffering from Erectile Dysfunction

Authors

ŠRÁMKOVÁ Taťána ŠRÁMKOVÁ K. JARKOVSKÝ Jiří POHANKA Michal ČERMÁK Aleš

Year of publication 2020
Type Article in Periodical
Magazine / Source Biomedical Journal of Scientific & Technical Research
MU Faculty or unit

Faculty of Medicine

Citation
Web https://biomedres.us/fulltexts/BJSTR.MS.ID.004386.php
Doi http://dx.doi.org/10.26717/BJSTR.2020.26.004386
Keywords Erectile Dysfunction; Diabetes Type 2; Endothelial Dysfunction; Topical Alprostadil; International Index of Erectile Function; Erectile Hardness Score
Description Aims: Erectile and endothelial dysfunctions are the most common complications of diabetes. We studied the endothelial function and response to treatment of a topical alprostadil in diabetics with erectile dysfunction. Sample and Methods: 30 patients were enrolled in the non-intervention, postregistration, prospective study with 300 (MU)g alprostadil cream. We examined vascular endothelial function using an ENDO-PAT 2000 device. We used International Index of Erectile Function (IIEF-5), Erectile Hardness Score (EHS), Global Assessment Questionnaire (GAQ) and Sexual Encounter Profile Q 2 and 3 (SEP 2, SEP 3) to assess erectile function. The primary outcome measures were the proportion of patients with an optimal treatment response at baseline and at 6 and 12 weeks after treatment and the evaluation of patients and their partner’s subjective satisfaction. Results: We diagnosed endothelial dysfunction in 15 diabetics. After 12 weeks of treatment with alprostadil 53.3% of the sample, reached normal erectile function. We found a significant increase in IIEF-5 scores with a median of 6 points (range 0–19, p<0.001) after 6 weeks compared to baseline, and of 7 points (range 0–20, p<0.001) after 12 weeks of treatment compared to baseline; a significant increase occurred both after 6 and 12 weeks of treatment (p=0.002). After both 6 and 12 weeks we found a significant increase in erection rigidity, EHS, compared to baseline (p< 0.001, p = 0.014). After 12 weeks of treatment, GAQ, improving erectile function was reached in 76.7% patients. Conclusion: We have demonstrated that topical alprostadil is efficient in diabetic men with erectile-endothelial dysfunction.

You are running an old browser version. We recommend updating your browser to its latest version.

More info